Karen Visser

1.8k citations

27 papers · 1.0k indexed · 1 hit paper · h-index 17

Rheumatology top 2%
Surgery
Pulmonary and Respiratory Medicine top 10%
Radiology, Nuclear Medicine and Imaging top 10%
Hematology top 5%

Co-authors: M. G. Myriam Hunink T. Huizinga Cornelia F Allaart André J. Peeters H. K. Ronday I. Speyer Jill van Aken Leroy R. Lard
Topics: Rheumatoid Arthritis Research and Therapies (12 papers)Lymphoma Diagnosis and Treatment (8 papers)Autoimmune and Inflammatory Disorders Research (6 papers)
Cited by: Rheumatology Hematology Internal Medicine
Journals: The Lancet Radiology Annals of the Rheumatic Diseases
Partner nations: Netherlands United Kingdom United States

In The Last Decade

Karen Visser

26 papers receiving 985 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial

2022 96 citations Marloes Verstappen, Yousra J. Dakkak et al. The Lancet profile →

Peers

Countries citing papers authored by Karen Visser

Since Specialization

Citations

This map shows the geographic impact of Karen Visser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Visser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Visser more than expected).

Fields of papers citing papers by Karen Visser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Visser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Visser. The network helps show where Karen Visser may publish in the future.

Co-authorship network of co-authors of Karen Visser

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Visser. A scholar is included among the top collaborators of Karen Visser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Visser. Karen Visser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disease-modifying antirheumatic drug–free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study 2025 ·Annals of the Rheumatic Diseases ·(unknown),Marijn Vis,(unknown),Jolanda J. Luime,Marc R. Kok,Ilja Tchetverikov,Karen Visser,(unknown),J. Bijsterbosch,M. van Oosterhout,Paul Baudoin,(unknown),Annette H M van der Helm–van Mil,Pascal H P de Jong	0
2	Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial 2024 ·The Lancet Rheumatology ·(unknown),(unknown),Karen Visser,Leroy R. Lard,Annette H M van der Helm–van Mil	5
3	Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trialbreakdown → 2022 ·The Lancet ·(unknown),Marloes Verstappen,(unknown),Yousra J. Dakkak,L.E. Burgers,Aleid C. Boer,(unknown),(unknown),Karen Visser,Marc R. Kok,Esmeralda T. H. Molenaar,Pascal H P de Jong,Stefan Böhringer,T. Huizinga,Cornelia F Allaart,Ellis Niemantsverdriet,Annette H M van der Helm–van Mil	96
4	Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment 2015 ·Lara D. Veeken ·(unknown),L. Heimans,Karen Visser,Anne A. Schouffoer,Esmeralda T. H. Molenaar,J.H.L.M. van Groenendael,André J. Peeters,I. Speyer,(unknown),T. Huizinga,Cornelia F Allaart	11
5	Personalized medicine: predicting responses to therapy in patients with RA 2013 ·Current Opinion in Pharmacology ·Marianne van den Broek,Karen Visser,Cornelia F Allaart,T. Huizinga	24
6	Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study) 2013 ·Annals of the Rheumatic Diseases ·Jill van Aken,L. Heimans,(unknown),Karen Visser,H. K. Ronday,I. Speyer,André J. Peeters,T. Huizinga,Cornelia F Allaart	33
7	‘Every picture tells a story’: Interviews and diaries with children with cerebral palsy about adapted cycling 2013 ·Journal of Paediatrics and Child Health ·(unknown),(unknown),Karen Visser,(unknown)	17
8	Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study) 2012 ·Annals of the Rheumatic Diseases ·(unknown),Karen Visser,L. Heimans,H. K. Ronday,Esmeralda T. H. Molenaar,J.H.L.M. van Groenendael,André J. Peeters,(unknown),(unknown),P. B. J. de Sonnaville,Bernard Grillet,T. Huizinga,Cornelia F Allaart	78
9	Adapted bikes – what children and young people with cerebral palsy told us about their participation in adapted dynamic cycling 2012 ·Disability and Rehabilitation Assistive Technology ·(unknown),(unknown),Karen Visser,(unknown)	37
10	Being a Voluntary Teacher in the Maldives 2011 ·ACCESS Access to science business innovation in digital economy ·Karen Visser	1
11	Validity of the disease activity score in undifferentiated arthritis 2010 ·Arthritis Care & Research ·Jaap Fransen,Karen Visser,(unknown),T. Huizinga,Piet L. C. M. van Riel,Désirée van der Heijde	8
12	Methotrexate in rheumatoid arthritis: experience and recommendations from the 3E initiative 2009 ·International Journal of Clinical Rheumatology ·Karen Visser,Désirée van der Heijde,Maxime Dougados	2
13	Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trial 2007 ·Arthritis & Rheumatism ·(unknown),Jill van Aken,Leroy R. Lard,Karen Visser,H. K. Ronday,(unknown),I. Speyer,(unknown),André J. Peeters,Cornelia F Allaart,René E. M. Toes,Ferdinand C. Breedveld,T. Huizinga	290
14	Interobserver Agreement for the Interpretation of Contrast-Enhanced 3D MR Angiography and MDCT Angiography in Peripheral Arterial Disease 2005 ·American Journal of Roentgenology ·Rody Ouwendijk,Marc C. J. M. Kock,Karen Visser,Peter M. T. Pattynama,Michiel W. de Haan,M. G. Myriam Hunink	34
15	Peripheral Arterial Disease: Sensitivity-encoded Multiposition MR Angiography Compared with Intraarterial Angiography and Conventional Multiposition MR Angiography 2004 ·Radiology ·(unknown),Harrie C. M. van den Bosch,Alexander V. Tielbeek,(unknown),Karen Visser,M. G. Myriam Hunink,Lucien E. M. Duijm,(unknown),Jaap Buth,(unknown)	35
16	Living Renal Donors: Optimizing the Imaging Strategy—Decision- and Cost-effectiveness Analysis 2003 ·Radiology ·Ylian S. Liem,Marc C. J. M. Kock,Jan N.M. IJzermans,Willem Weimar,Karen Visser,M. G. Myriam Hunink	18
17	Cost-effectiveness Targets for Multi–Detector Row CT Angiography in the Work-up of Patients with Intermittent Claudication 2003 ·Radiology ·Karen Visser,Marc C. J. M. Kock,Karen M. Kuntz,Magruder C. Donaldson,G. Scott Gazelle,M. G. Myriam Hunink	25
18	Intermittent Claudication: Cost-effectiveness of Revascularization versus Exercise Therapy 2002 ·Radiology ·Sybolt O. de Vries,Karen Visser,(unknown),John B. Wong,Magruder C. Donaldson,M. G. Myriam Hunink	62
19	Duplex scan surveillance during the first year after infrainguinal autologous vein bypass grafting surgery: Costs and clinical outcomes compared with other surveillance programs 2001 ·Journal of Vascular Surgery ·Karen Visser,Mirza M. Idu,Jacob Buth,Gerard L. Engel,M. G. Myriam Hunink	31
20	Peripheral Arterial Disease: Gadolinium-enhanced MR Angiography versus Color-guided Duplex US—A Meta-analysis 2000 ·Radiology ·Karen Visser,M. G. Myriam Hunink	142

About Karen Visser

Karen Visser is a scholar working on Rheumatology, Hematology and Pathology and Forensic Medicine, having authored 27 papers that have together received 1.0k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (12 papers), Lymphoma Diagnosis and Treatment (8 papers) and Autoimmune and Inflammatory Disorders Research (6 papers). The work is most often cited by research in Rheumatology (534 citations), Hematology (182 citations) and Internal Medicine (48 citations). Karen Visser has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include M. G. Myriam Hunink, T. Huizinga, Cornelia F Allaart, André J. Peeters, H. K. Ronday, I. Speyer, Jill van Aken, Leroy R. Lard, Ferdinand C. Breedveld and René E. M. Toes. Their work appears in journals such as The Lancet, Radiology and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact